Janus Kinase (JAK) Inhibitors Clinical Trials 2024: FDA Approvals, Clinical Trials, Medication, Therapies, Mechanism of Action, Route of Administration, and Companies by DelveInsight

(Albany, United States) As per DelveInsight's assessment, globally, Janus Kinase (JAK) Inhibitors pipeline constitutes key companies continuously working towards developing Janus Kinase (JAK) Inhibitors treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

"Janus Kinase (JAK) Inhibitors Pipeline Insight, 2024" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Janus Kinase (JAK) Inhibitors Market.
The Janus Kinase (JAK) Inhibitors Pipeline report provides a comprehensive commercial and clinical evaluation of pipeline products, spanning from the pre-clinical development phase to the marketed phase. This report includes detailed descriptions of the drugs, covering their mechanisms of action, clinical studies, NDA approvals (if any), and various product development activities. These activities encompass technology, collaborations, mergers and acquisitions, funding, designations, and other relevant product-related information.

Request for sample report @ https://www.delveinsight.com/sample-request/janus-kinase-jak-inhibitor-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Some of the key takeaways from the Janus Kinase (JAK) Inhibitors Pipeline Report:
• Janus Kinase (JAK) Inhibitors Companies across the globe are diligently working toward developing novel Janus Kinase (JAK) Inhibitors treatment therapies with a considerable amount of success over the years.
• Janus Kinase (JAK) Inhibitors companies working in the treatment market are Sareum, Chipscreen Biosciences, Aclaris Therapeutics, Pfizer, EQRx, Celon Pharma, Theravance Biopharma, Reistone Biopharma, Concert Pharmaceuticals, Incyte Corporation, and others, are developing therapies for the Janus Kinase (JAK) Inhibitors treatment
• Emerging Janus Kinase (JAK) Inhibitors therapies in the different phases of clinical trials are- SDC-1801, CS-32582, ATI-2138, PF-07295324, EQ-121, CPL409116, TD-0903, Ivarmacitinib, CTP-543, Povorcitinib, and others are expected to have a significant impact on the Janus Kinase (JAK) Inhibitors market in the coming years.
• In December 2022, Incyte Corporation has commenced a Phase III clinical trial, employing a double-blind, randomized, and placebo-controlled design, to assess the efficacy and safety of povorcitinib (INCB054707) in individuals with moderate to severe hidradenitis suppurativa. The study spans a 12-week placebo-controlled phase, followed by a 42-week extension period. The anticipated completion date for the trial is March 2025, with an estimated enrollment of 600 participants.
• In October 2022, AbbVie revealed that the U.S. Food and Drug Administration (FDA) has granted approval for upadacitinib (marketed as Rinvoq), a Janus kinase (JAK) inhibitor. The approval is specifically for adults diagnosed with non-radiographic axial spondyloarthritis (nr-axSpA) exhibiting objective signs of inflammation and experiencing an inadequate response to or intolerance of one or more tumor necrosis factor (TNF) inhibitors.
• In October 2022, Incyte reported that findings from the crucial Phase III TRuE-V clinical trial program, which assessed the efficacy of ruxolitinib cream (marketed as OpzeluraTM) at a 1.5% concentration in patients aged 12 and above diagnosed with nonsegmental vitiligo, have been published in "The New England Journal of Medicine (NEJM)."
• In September 2022, Bristol Myers Squibb has unveiled new two-year findings from the POETYK PSO long-term extension (LTE) trial, revealing that continuous treatment with Sotyktu™ (deucravacitinib) maintains clinical efficacy in adult patients with moderate-to-severe plaque psoriasis. This assessment focused on patients who transitioned from the pivotal POETYK PSO-1 trial into the LTE trial. After 112 weeks of Sotyktu treatment, response rates, as per modified non-responder imputation (mNRI), were 82.4% for Psoriasis Area and Severity Index (PASI) 75, 55.2% for PASI 90, and 66.5% for static Physician's Global Assessment (sPGA) 0/1.
• In July 2022, AbbVie has reported the submission of applications to the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for a new indication for upadacitinib (marketed as RINVOQ®, with an induction dose of 45 mg and maintenance doses of 15 mg and 30 mg). This new indication aims to secure approval for the treatment of adult patients dealing with moderately to severely active Crohn's disease.

Janus Kinase (JAK) Inhibitors Overview
Janus Kinase (JAK) inhibitors are a class of medications targeting the Janus kinase family of enzymes, which play a pivotal role in the signaling pathways of various cytokines and growth factors involved in hematopoiesis, immune function, and inflammation. Dysregulation of JAK signaling is implicated in numerous diseases, including rheumatoid arthritis, psoriasis, inflammatory bowel disease, and certain types of cancers.
JAK inhibitors work by selectively blocking the activity of one or more JAK enzymes (JAK1, JAK2, JAK3, and TYK2), thereby modulating the immune response and reducing inflammation. The development of JAK inhibitors has rapidly progressed, with several drugs already approved and many others in various stages of clinical trials. These inhibitors offer a targeted approach to treatment, often with better efficacy and safety profiles compared to traditional therapies.
Commercially, the JAK inhibitor market is thriving, driven by substantial investments and collaborations among pharmaceutical companies and research institutions. The market is characterized by a dynamic landscape of mergers, acquisitions, and funding initiatives aimed at advancing the development and commercialization of these therapies. Given their significant therapeutic potential, JAK inhibitors continue to attract robust research and development efforts, representing a promising avenue for the treatment of various autoimmune and inflammatory diseases.

Get a Free Sample PDF Report to know more about Janus Kinase (JAK) Inhibitors Pipeline Therapeutic Assessment- https://www.delveinsight.com/report-store/janus-kinase-jak-inhibitor-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Emerging Janus Kinase (JAK) Inhibitors Drugs Under Different Phases of Clinical Development Include:
• SDC-1801: Sareum
• CS-32582: Chipscreen Biosciences
• ATI-2138: Aclaris Therapeutics
• PF-07295324: Pfizer
• EQ-121: EQRx
• CPL409116: Celon Pharma
• TD-0903: Theravance Biopharma
• Ivarmacitinib: Reistone Biopharma
• CTP-543: Concert Pharmaceuticals
• Povorcitinib: Incyte Corporation

Janus Kinase (JAK) Inhibitors Pipeline Therapeutics Assessment
• Janus Kinase (JAK) Inhibitors Assessment by Product Type
• Janus Kinase (JAK) Inhibitors By Stage and Product Type
• Janus Kinase (JAK) Inhibitors Assessment by Route of Administration
• Janus Kinase (JAK) Inhibitors By Stage and Route of Administration
• Janus Kinase (JAK) Inhibitors Assessment by Molecule Type
• Janus Kinase (JAK) Inhibitors by Stage and Molecule Type

DelveInsight's Janus Kinase (JAK) Inhibitors Report covers around products under different phases of clinical development like
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Further Janus Kinase (JAK) Inhibitors product details are provided in the report. Download the Janus Kinase (JAK) Inhibitors pipeline report to learn more about the emerging Janus Kinase (JAK) Inhibitors therapies at: https://www.delveinsight.com/sample-request/janus-kinase-jak-inhibitor-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Some of the key companies in the Janus Kinase (JAK) Inhibitors Therapeutics Market include:
Key companies developing therapies for Janus Kinase (JAK) Inhibitors are - Pfizer, Sierra Oncology, Theravance Biopharma, Dizal Pharmaceutical, Aclaris Therapeutics, Celon Pharma, Incyte Corporation, AbbVie, Galapagos, Gilead Sciences, Reistone Biopharma, Jiangsu Hengrui Medicine Co., Novartis Pharmaceuticals, Eli Lilly and Company, Kartos Therapeutics, Telios Pharma, Kiniksa Pharmaceuticals, Celgene, GlaxoSmithKline, Abivax S.A., Dizal Pharmaceuticals, Constellation Pharmaceuticals, MaaT Pharma, Galvani Bioelectronics, CTI BioPharma, Crescendo Bioscience, Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Astellas Pharma, Imago BioSciences, and others.

Janus Kinase (JAK) Inhibitors Pipeline Analysis:
The Janus Kinase (JAK) Inhibitors pipeline report provides insights into
• The report provides detailed insights about companies that are developing therapies for the treatment of Janus Kinase (JAK) Inhibitors with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Janus Kinase (JAK) Inhibitors Treatment.
• Janus Kinase (JAK) Inhibitors key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Janus Kinase (JAK) Inhibitors Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Janus Kinase (JAK) Inhibitors market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Janus Kinase (JAK) Inhibitors drugs and therapies- https://www.delveinsight.com/sample-request/janus-kinase-jak-inhibitor-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Janus Kinase (JAK) Inhibitors Pipeline Market Drivers
• Rising prevalence of chronic and autoimmune disease, increasing research and development projects for the launch of new drugs are some of the important factors that are fueling the Janus Kinase (JAK) Inhibitors Market.

Janus Kinase (JAK) Inhibitors Pipeline Market Barriers
• However, high cost of treatment, regulatory challenges in the launch of JAK inhibitors and other factors are creating obstacles in the Janus Kinase (JAK) Inhibitors Market growth.

Scope of Janus Kinase (JAK) Inhibitors Pipeline Drug Insight
• Coverage: Global
• Key Janus Kinase (JAK) Inhibitors Companies: Sareum, Chipscreen Biosciences, Aclaris Therapeutics, Pfizer, EQRx, Celon Pharma, Theravance Biopharma, Reistone Biopharma, Concert Pharmaceuticals, Incyte Corporation, and others
• Key Janus Kinase (JAK) Inhibitors Therapies: SDC-1801, CS-32582, ATI-2138, PF-07295324, EQ-121, CPL409116, TD-0903, Ivarmacitinib, CTP-543, Povorcitinib, and others
• Janus Kinase (JAK) Inhibitors Therapeutic Assessment: Janus Kinase (JAK) Inhibitors current marketed and Janus Kinase (JAK) Inhibitors emerging therapies
• Janus Kinase (JAK) Inhibitors Market Dynamics: Janus Kinase (JAK) Inhibitors market drivers and Janus Kinase (JAK) Inhibitors market barriers

Request for Sample PDF Report for Janus Kinase (JAK) Inhibitors Pipeline Assessment and clinical trials- https://www.delveinsight.com/sample-request/janus-kinase-jak-inhibitor-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Table of Contents
1. Janus Kinase (JAK) Inhibitors Report Introduction
2. Janus Kinase (JAK) Inhibitors Executive Summary
3. Janus Kinase (JAK) Inhibitors Overview
4. Janus Kinase (JAK) Inhibitors- Analytical Perspective In-depth Commercial Assessment
5. Janus Kinase (JAK) Inhibitors Pipeline Therapeutics
6. Janus Kinase (JAK) Inhibitors Late Stage Products (Phase II/III)
7. Janus Kinase (JAK) Inhibitors Mid Stage Products (Phase II)
8. Janus Kinase (JAK) Inhibitors Early Stage Products (Phase I)
9. Janus Kinase (JAK) Inhibitors Preclinical Stage Products
10. Janus Kinase (JAK) Inhibitors Therapeutics Assessment
11. Janus Kinase (JAK) Inhibitors Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Janus Kinase (JAK) Inhibitors Key Companies
14. Janus Kinase (JAK) Inhibitors Key Products
15. Janus Kinase (JAK) Inhibitors Unmet Needs
16 . Janus Kinase (JAK) Inhibitors Market Drivers and Barriers
17. Janus Kinase (JAK) Inhibitors Future Perspectives and Conclusion
18. Janus Kinase (JAK) Inhibitors Analyst Views
19. Appendix
20. About DelveInsight

Trending Report :
• Hearing Aid Devices Market: https://www.delveinsight.com/report-store/audiology-devices-market
• Alstrom Syndrome Market: https://www.delveinsight.com/report-store/bardet-biedl-syndrome-market
• Arteriovenous Fistula Market: https://www.delveinsight.com/report-store/arteriovenous-fistula-market
• Prefilled Syringes Market: https://www.delveinsight.com/report-store/prefilled-syringes-market
• Post-transplant Lymphoproliferative Disease Market: https://www.delveinsight.com/report-store/post-transplant-lymphoproliferative-disorder-market
• Adult Onset Still Disease Market: https://www.delveinsight.com/report-store/adult-onset-still-disease-market
• Cardiac Resynchronization Therapy Device Market: https://www.delveinsight.com/report-store/cardiac-resynchronization-therapy-market
• Chronic Inflammatory Demyelinating Polyneuropathy Market: https://www.delveinsight.com/report-store/chronic-inflammatory-demyelinating-polyneuropathy-cidp-market
• Carcinoid Tumor Market: https://www.delveinsight.com/report-store/neuroendocrine-tumors-market
• Nsclc Market: https://www.delveinsight.com/report-store/non-small-cell-lung-cancer-nsclc-market
• Opioid Induced Constipation Market: https://www.delveinsight.com/report-store/opioid-induced-constipation-market
• Bronchiolitis Obliterans Syndrome Bos Market: https://www.delveinsight.com/report-store/bronchiolitis-obliterans-syndrome-market
• Necrotizing Enterocolitis Market: https://www.delveinsight.com/report-store/necrotizing-enterocolitis-nec-epidemiology-forecast
• Acute Coronary Syndrome Market: https://www.delveinsight.com/report-store/acute-coronary-syndrome-market
• Epilepsy Market: https://www.delveinsight.com/report-store/epilepsy-market
• Image Guided Surgery Devices Market: https://www.delveinsight.com/report-store/image-guided-surgery-devices-market
• Progressive Familial Intrahepatic Cholestasis Market: https://www.delveinsight.com/report-store/progressive-familial-intrahepatic-cholestasis-pfic-market
• Anterior Cruciate Ligament Injuries Market: https://www.delveinsight.com/report-store/anterior-cruciate-ligament-injuries-market
• Automated External Defibrillators Market: https://www.delveinsight.com/report-store/automated-external-defibrillator-aed-market
• Cervical Cancer Market Size: https://www.delveinsight.com/report-store/cervical-cancer-market
• Chronic Lymphocytic Leukemia Market: https://www.delveinsight.com/report-store/chronic-lymphocytic-leukemia-cll-market
• Neurotrophic Keratitis Market: https://www.delveinsight.com/report-store/neurotrophic-keratitis-market
• Neurovascular Devices Market: https://www.delveinsight.com/report-store/neurovascular-devices-interventional-neurology-market
• Optic Neuritis Market: https://www.delveinsight.com/report-store/optic-neuritis-market
• Spasticity Market: https://www.delveinsight.com/report-store/spasticity-market
• Surgical Stapling Devices Market: https://www.delveinsight.com/report-store/surgical-stapling-devices-market
• Thrombotic Microangiopathy Market: https://www.delveinsight.com/report-store/thrombotic-microangiopathy-tma-market
• Vestibular Schwannoma Market: https://www.delveinsight.com/report-store/vestibular-schwannoma-market

Contact Us:
Ankit Nigam
Manager Marketing
info@delveinsight.com
+14699457679
https://www.delveinsight.com/consulting/conference-coverage-services

About DelveInsight
DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.

This release was published on openPR.